QBKPN SSI

Drug Profile

QBKPN SSI

Alternative Names: Lung targeted site specific immunomodulator - Qu Biologics

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Qu Biologics
  • Class Bacterial antigens; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 24 Mar 2017 Phase-IIa development for Non-small cell lung cancer is ongoing in Canada (SC)
  • 01 Nov 2016 Qu Biologics withdraws phase I trial in Non-small cell lung cancer (In volunteers), prior to enrolment, in Canada (NCT02897999)
  • 07 Sep 2016 Qu Biologics plans a phase I trial in Healthy volunteers in Canada (SC) (NCT02897999)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top